{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000495","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.331780+00:00","generated_at":"2026-06-20T18:26:40.634856+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sarepta prelim Q4 revenue $235.5M, FY $843.3M, exceeding guidance","bullets":["Preliminary Q4 2022 net product revenue ~$235.5M, up 32% YoY.","Full-year 2022 net product revenue ~$843.3M, up 38% YoY, exceeding guidance of $825-840M.","Year-end cash balance ~$2.0B, down slightly from $2.1B at end of 2021.","Revenues from three RNA-based PMO therapies: EXONDYS 51, VYONDYS 53, AMONDYS 45.","Final Q4/FY results expected in late February 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000495","json":"https://secwatch.observer/filing/0000950170-23-000495.json","markdown":"https://secwatch.observer/filing/0000950170-23-000495.md","text":"https://secwatch.observer/filing/0000950170-23-000495.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000095017023000495/0000950170-23-000495-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000095017023000495/srpt-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:26:40.634856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"372a1302e0f6cc9960342e696d8c18a67a8f58fc","claim":"Sarepta Therapeutics, Inc. reported year ended December 31, 2022 results: revenue approximately $843.3 million.","evidence_excerpt":"expects total net product revenue (unaudited) for the year ended December 31, 2022 to be approximately $843.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000095017023000495/0000950170-23-000495-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Revenue","value":"approximately $843.3 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"721c19047d39dd53a3544555cf872c171b43e2ed","claim":"Sarepta Therapeutics, Inc. reported fourth quarter ended December 31, 2022 results: revenue approximately $235.5 million.","evidence_excerpt":"the Company expects total net product revenue (unaudited) for the fourth quarter ended December 31, 2022 to be approximately $235.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000095017023000495/0000950170-23-000495-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"approximately $235.5 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}